Target | Agent | Application | Status | Reference |
PD-1 | Nivolumab | Melanoma | Approved | (12) |
Lung cancer | Approved | (36) | ||
Renal cell cancer | Approved | (37) | ||
Pembrolizumab | Melanoma | Approved | (11) | |
Lung cancer | In phase I clinical trials | (38) | ||
PD-L1 | Atezolizumab | Lung cancer | In phase II clinical trials | (39) |
Bladder cancer | In phase II clinical trials | (40) | ||
CTLA-4 | Tremelimumab | Melanoma | In phase III clinical trials | (26) |
Ipilimumab | Melanoma | Approved | (25) |